Amyloid-related imaging abnormalities (ARIA) are a recognized complication of anti-amyloid monoclonal antibodies for Alzheimer's disease (AD). While typically asymptomatic, a subset of patients develops severe clinical symptoms and radiological findings requiring intensive management. Data on their presentation, treatment, and outcomes remain limited.
Objective
We report two cases and analyze the clinical features of all published cases of severe symptomatic ARIA, with a focus on associated risk factors, therapeutic approaches, and patient outcomes.
Methods
We report two cases of severe symptomatic ARIA in patients treated with gantenerumab. A systematic review was conducted following PRISMA guidelines using MEDLINE, Web of Science, and manual reference screening. We included case reports and series providing individual-level data on symptomatic ARIA episodes classified as severe by clinical criteria. Demographic, genetic, clinical, radiological, therapeutic, and outcome data were extracted.
Results
Thirty-six cases were included (2 new and 34 from 21 publications). Fifteen cases were associated with lecanemab, 10 with gantenerumab, 6 with donanemab, and 5 with other antibodies. APOE ε4 was present in 62.5%, including 10 ε4/ε4 homozygotes. Baseline MRI showed hemorrhagic markers in 10 cases, including superficial siderosis in 2 of the 5 patients with isolated macrohemorrhages. Most episodes occurred within 6 months of treatment. Symptoms included altered consciousness (75%), focal deficits (66.7%), seizures (38.9%), and headache (36.1%). ARIA-E resolved in all non-fatal cases. Corticosteroids were used in 72%. Among the patients whose outcome data were available, 15 patients recovered completely, 10 had persistent deficits, and 10 died.
Conclusions
Severe symptomatic ARIA is a rare but serious adverse effect of anti-amyloid therapy. Standardized diagnostic and therapeutic guidelines are needed to minimize ARIA-related morbidity and mortality.
SchenkD. Amyloid-beta immunotherapy for Alzheimer’s disease: the end of the beginning. Nat Rev Neurosci2002; 3: 824–828.
2.
JuckerMWalkerLC. Alzheimer’s disease: from immunotherapy to immunoprevention. Cell2023; 186: 4260–4270.
3.
DoodyRSThomasRGFarlowM, et al.Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med2014; 370: 311–321.
4.
OstrowitzkiSBittnerTSinkKM, et al.Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol2022; 79: 1113–1121.
5.
van DyckCHSwansonCJAisenP, et al.Lecanemab in early Alzheimer’s disease. N Engl J Med2023; 388: 9–21.
6.
Budd HaeberleinSAisenPSBarkhofF, et al.Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis2022; 9: 197–210.
7.
SimsJRZimmerJAEvansCD, et al.Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA2023; 330: 512–527.
8.
BatemanRJSmithJDonohueMC, et al.Two phase 3 trials of gantenerumab in early Alzheimer’s disease. N Engl J Med2023; 389: 1862–1876.
9.
SperlingRAJackCRBlackSE, et al.Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s association research roundtable workgroup. Alzheimers Dement2011; 7: 367–385.
10.
HampelHElhageAChoM, et al.Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain2023; 146: 4414–4424.
SallowaySChalkiasSBarkhofF, et al.Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol2022; 79: 13–21.
13.
VandenbergheRRinneJOBoadaM, et al.Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther2016; 8: 18.
14.
HonigLSSabbaghMNvan DyckCH, et al.Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease. Alzheimers Res Ther2024; 16: 105.
15.
SallowaySWojtowiczJVoyleN, et al.Amyloid-related imaging abnormalities (ARIA) in clinical trials of gantenerumab in early Alzheimer disease. JAMA Neurol2025; 82: 19–29.
16.
ZimmerJAArdayfioPWangH, et al.Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials. JAMA Neurol2025; 82: 461–469.
17.
SallowaySPSchragMSaverJL. Heed the warning signs to avoid serious ARIA. Neurology2024; 103: e209674.
18.
BrashearHRKetterNBogertJ, et al.Clinical evaluation of amyloid-related imaging abnormalities in bapineuzumab phase III studies. J Alzheimers Dis2018; 66: 1409–1424.
19.
GagnierJJKienleGAltmanDG, et al.The CARE guidelines: consensus-based clinical case report guideline development. J Clin Epidemiol2014; 67: 46–51.
20.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J2021; 372: n71.
21.
MoolaSMunnZTufanaruC, et al.Chapter 7: Systematic reviews of etiology and risk. In: AromatarisEMunnZ (eds) Joanna Briggs Institute Reviewer’s Manual. The Joanna Briggs Institute, 2017. https://reviewersmanual.joannabriggs.org/.
22.
BarkhofFDaamsMScheltensP, et al.An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion. AJNR Am J Neuroradiol2013; 34: 1550–1555.
23.
ZavarellaMCecchettiGRugarliG, et al.Favorable long-term cognitive outcomes following recurrent ARIA linked to amyloid-lowering therapies: two cases. J Neurol2025; 272: 168.
24.
VandeVredeLGibbsDMKoestlerM, et al.Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab. Alzheimers Dement (Amst)2020; 12: e12101.
25.
Neves BriardJDuquetteACayrolR, et al.Refractory status epilepticus in a patient with aducanumab-induced amyloid-related imaging abnormalities. Neurology2024; 103: e209582.
26.
BonomiSSamaraABalestraN, et al.Teaching neuroimage: severe amyloid-related imaging abnormalities after anti-β-amyloid monoclonal antibody treatment. Neurology2023; 101: 1079–1080.
27.
CzerminskiJKhatriSRaoB. Amyloid related imaging abnormalities in the emergency setting. Emerg Radiol2024; 31: 937–941.
28.
CastellaniRJShanesEDMcCordM, et al.Neuropathology of anti-amyloid-β immunotherapy: a case report. J Alzheimers Dis2023; 93: 803–813.
29.
GibsonAWElserHRossoM, et al.Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemab. Alzheimers Dement2024; 20: 8192–8197.
30.
JiSRosenbloomM. Intracerebral hemorrhage following mild ARIA-H in an APOE ε2 carrier receiving lecanemab. Alzheimers Res Ther2024; 16: 265.
31.
SolopovaERomero-FernandezWHarmsenH, et al.Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer’s disease. Nat Commun2023; 14: 8220.
32.
WatanabeMOkochiRTezukaT, et al.Spontaneous haemorrhage in subdural hygroma in an Alzheimer’s patient on lecanemab. BMJ Case Rep2025; 18: e263497.
33.
YamazakiASekineTTakahashiS, et al.A case of severe ARIA with multiple infarctions and extensive microbleeds following lecanemab administration. Psychogeriatrics2025; 25: e13231.
34.
RosenbloomMSchneeANimmaS, et al.Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics. J Neurol2025; 272: 394.
35.
PaczynskiMHofmannAPoseyZ, et al.Lecanemab treatment in a specialty memory clinic. JAMA Neurol2025; 82: 655–665.
36.
RoherAEMaaroufCLDaugsID, et al.Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient. J Alzheimers Dis2011; 24: 315–325.
37.
ReishNJJamshidiPStammB, et al.Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N Engl J Med2023; 388: 478–479.
Eli Lilly and Company. Donanemab for the treatment of patients with early symptomatic Alzheimeŕs disease. Sponsor's briefing document, www.fda.gov/media/179167/download (2024).
40.
ZhaoKBarotNFriedmanG, et al.Medically refractory nonconvulsive status epilepticus in ARIA with lecanemab (P1-3.017). Neurology2025; 104. DOI: 10.1212/WNL.0000000000212014
41.
SperlingRSallowaySBrooksDJ, et al.Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol2012; 11: 241–249.
42.
SriwastavaSKatariaSSrivastavaS, et al.Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: a systematic review and meta-analysis. J Neuroimmunol2021; 360: 577721.
43.
TheodorouAPalaiodimouLMalhotraK, et al.Clinical, neuroimaging, and genetic markers in cerebral amyloid angiopathy-related inflammation: a systematic review and meta-analysis. Stroke2023; 54: 178–188.
44.
SöderbergLJohannessonMGkanatsiouE, et al.Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities. Sci Rep2024; 14: 10868.
45.
FilippiMCecchettiGSpinelliEG, et al.Amyloid-related imaging abnormalities and β-amyloid–targeting antibodies: a systematic review. JAMA Neurol2022; 79: 291.
46.
LoomisSJMillerRCastrillo-VigueraC, et al.Genome-wide association studies of ARIA from the aducanumab phase 3 ENGAGE and EMERGE studies. Neurology2024; 102: e207919.
47.
CummingsJApostolovaLRabinoviciGD, et al.Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis2023; 10: 362–377.
48.
RabinoviciGDSelkoeDJSchindlerSE, et al.Donanemab: appropriate use recommendations. J Prev Alzheimers Dis2025; 12: 100150.
49.
WangHSerap Monkul NeryEArdayfioP, et al.Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. Alzheimers Dement2025; 21: e70062.
50.
CogswellPMBarakosJABarkhofF, et al.Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice. AJNR Am J Neuroradiol2022; 43: E19–E35.
51.
CharidimouABoulouisGFroschMP, et al.The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol2022; 21: 714–725.
52.
AntoliniLDiFrancescoJCZeddeM, et al.Spontaneous ARIA-like events in cerebral amyloid angiopathy-related inflammation: a multicenter prospective longitudinal cohort study. Neurology2021; 97: e1809–e1822.
53.
AurielECharidimouAGurolME, et al.Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation. JAMA Neurol2016; 73: 197–202.
54.
Martín-JiménezPSánchez-TorneroMLlamas-VelascoS, et al.Cerebral amyloid angiopathy-related inflammation: clinical features and treatment response in a case series. Neurologia2023; 38: 550–559.
55.
RegenhardtRWThonJMDasAS, et al.Association between immunosuppressive treatment and outcomes of cerebral amyloid angiopathy-related inflammation. JAMA Neurol2020; 77: 1261–1269.
56.
HuangJLongXChenC. A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system. Front Pharmacol2025; 16: 1522058.
57.
YanLZhangLXuZ, et al.A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab. Front Pharmacol2025; 16: 1559447.
58.
AljuhaniMAshrafAEdisonP. Evaluating clinical meaningfulness of anti-β-amyloid therapies amidst amyloid-related imaging abnormalities concern in Alzheimer’s disease. Brain Commun2024; 6: fcae435.
59.
Castro CaldasASilvaCAlbuquerqueL, et al.Cerebral amyloid angiopathy associated with inflammation: report of 3 cases and systematic review. J Stroke Cerebrovasc Dis2015; 24: 2039–2048.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
